Skip to content

Moisturization and Skin Hydration Study

Understanding the Effect of Pre-Drying Moisturization on Skin Hydration

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07270965
Enrollment
30
Registered
2025-12-08
Start date
2025-12-31
Completion date
2026-12-31
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)

Keywords

Atopic Dermatitis, Eczema, AD, Moisturizer, Cream, Skin Hydration

Brief summary

Skin moisturization is important for patients with atopic dermatitis, commonly known as eczema. Moisturizing right after bathing is widely accepted as the best method to keep skin hydrated. However, there is conflicting research on the timing of moisturizing. The goal of this clinical study is to evaluate the preference of moisturizing while showering/bathing compared to after towel drying in adolescents aged 12-18 with eczema. The main question it aims to answer are: * Which moisturization technique is preferred: while showering/bathing or after towel drying? * How do these techniques affect investigator-assessed eczema severity, patient-reported itch scores, and objective skin hydration measurements? Researchers will compare applying moisturizer while in the shower/bath to after towel drying and to which technique is preferred among participants and if there are different effects on eczema and skin hydration. Participants will: * Apply moisturizer while showering/bathing for one month and after towel drying for one month. * Complete questionnaires on moisturization technique, skin feel, and itchiness. * Undergo skin hydration measurements using a Corneometer® CM825 device.

Interventions

BEHAVIORALMoisturizing while in shower/bath

Applying moisturizer in the shower/bath.

BEHAVIORALMoisturizing after towel drying

Applying moisturizer out of the shower/bath after towel drying.

Sponsors

L'Oreal
CollaboratorINDUSTRY
University of British Columbia
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Participants must have a diagnosis of atopic dermatitis/eczema. * Participants must be between the age of 12-18. * Participants must be able to bathe independently. * Participants will be English speaking and able to complete questionnaires.

Exclusion criteria

* Participants who use topical corticosteroids between one inch above the wrist and 1 inch below the elbow from 1 month on both arms prior to the study until the final visit. * Participants who have a known allergy to the moisturizer cream (Cerave Moisturizing Cream) provided.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Participants Preferring Each Moisturization TechniqueThrough study completion, an average of 2 months.Participant reported preference of moisturization technique

Secondary

MeasureTime frameDescription
Skin Hydration LevelThrough study completion, an average of 2 months.Skin electrical capacitance measured using Corneometer® CM825 as an indicator of skin hydration.

Other

MeasureTime frameDescription
Eczema Severity ScoreThrough study completion, an average of 2 months.Eczema severity will be assessed by clinicians using the Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD™). Scores range from 1 to 4, with higher scores indicating more severe eczema/atopic dermatitis (worse outcome).
Itch IntensityThrough study completion, an average of 2 months.Itch intensity will be assessed using a patient-reported Numeric Rating Scale (NRS) ranging from 1 to 10, where higher scores indicate greater itch severity (worse outcome). Participants will report both average itch and worst itch experienced within the past 24 hours.

Countries

Canada

Contacts

Primary ContactWingfield Rehmus, MD, MPH
dermatologyresearch@cw.bc.ca1-604-875-2606

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026